Healthcare, Pharma & Life Sciences

Senators Introduce Bill to Create Federally Chartered Heart Research Foundation

Image
Senators Introduce Bill to Create Federally Chartered Heart Research Foundation

Washington – September 26, 2026 -- A bipartisan bill introduced in the U.S. Senate would create the Heart Security Foundation, a federally chartered nonprofit housed within the National Institutes of Health to accelerate cardiovascular research funding and coordination.

Cardiovascular disease kills nearly one million Americans annually

Cardiovascular disease remains the leading cause of death in the United States, claiming close to one million lives each year, according to figures cited in the legislative push. Roughly 120 million American adults -- nearly one-third of the U.S. population -- are living with some form of cardiovascular disease, with risk levels disproportionately distributed across communities.

Gold Coast Health Plan Awards $2M to Ease Medi-Cal Rule Changes

Image
Gold Coast Health Plan Awards $2M to Ease Medi-Cal Rule Changes

Camarillo, Calif. – September 26, 2026 -- Gold Coast Health Plan (GCHP) has awarded $2,087,811 in one-year grants to seven providers and community organizations in Ventura County to help Medi-Cal members retain coverage ahead of new federal eligibility rules taking effect in 2027.

GCHP's RISE program brings cumulative community investment past $13 million

The 2026 round is the second year of GCHP's Resilience, Innovation, Sustainability & Equity (RISE) Grant Program, following $11.3 million distributed across 16 grants in 2025. The program has now invested more than $13 million into local providers and community groups since launch.

Baystate Health First in U.S. to Enroll Patients in PIONEER Aneurysm Trial

Image
Baystate Health First in U.S. to Enroll Patients in PIONEER Aneurysm Trial

Springfield, Mass. – September 26, 2026 -- Baystate Health has become the first hospital in the United States to enroll patients in the PIONEER trial, a national study evaluating Balt Corporation's Silk Vista Baby flow-diverting stent for unruptured brain aneurysms in small blood vessels, treating its first three patients within days of receiving approval.

Baystate enrolls first three U.S. patients in national aneurysm device trial

The PIONEER study is a prospective, multicenter, single-arm trial spanning 35 leading centers in the United States and 5 in Canada, designed to assess the safety and efficacy of the Silk Vista Baby device. Balt Corporation launched the trial to satisfy FDA requirements for broader U.S. market access after the device received full approval from the Centers for Medicare & Medicaid Services following a prolonged review process.

Spring Health Expands AI Safety Benchmark to Cover Harm From Others

Image
Spring Health Expands AI Safety Benchmark to Cover Harm From Others

New York – September 26, 2026 -- Spring Health has expanded VERA-MH, the first open-source AI safety benchmark for mental health, to add a second clinical safety area covering harm from others, as more users turn to AI systems for emotional support.

New rubric measures AI response to interpersonal violence risk

The VERA-MH Harm-From-Others rubric evaluates how AI systems respond when an adult describes being at risk of physical or sexual violence from another person. It scores responses across five areas: detecting risk, confirming it, guiding the person to human care, supportive conversation, and adherence to AI boundaries. The rubric draws on 100 realistic personas and was developed with clinicians, subject-matter experts in interpersonal violence, and people with lived experience.

Parker Health Group Names Mark Lenhard President & CEO

Image
Parker Health Group Names Mark Lenhard President & CEO

Piscataway, N.J. – September 26, 2026 -- Parker Health Group has named Mark Lenhard, MS, LNFA, as its next President & CEO, succeeding Roberto Muñiz after nearly 28 years of leadership at the nonprofit aging services provider.

Lenhard joins Parker in December 2026 from United Methodist Communities

Lenhard currently serves as President & CEO of United Methodist Communities (UMC) and the UMC Foundation, a faith-based nonprofit network spanning nine senior living communities, a home- and community-based services platform, a consulting arm, and a philanthropic foundation. He is expected to join Parker in December 2026.

IASO Bio's RD140 CAR-T Hits 88.9% Response Rate in Myeloma Trial

Shanghai – September 26, 2026 -- IASO Biotechnology reported an 88.9% objective response rate for its dual-targeted CAR-T therapy RD140 in a first-in-human Phase 1 trial of nine heavily pretreated multiple myeloma and plasma cell leukemia patients, with the response rate reaching 100% in the higher-dose cohort.

RD140 achieves 88.9% MRD negativity in high-risk relapsed patients

The investigator-initiated trial (NCT06655519), led by Professor Jin Lu of Peking University People's Hospital, enrolled patients who had failed at least three prior lines of therapy, including two who had previously received BCMA-targeted treatment. All nine patients were triple-class exposed, and six were penta-exposed. As of the September 26, 2026 data cutoff, with a median follow-up of 6.05 months, 88.9% of patients achieved MRD negativity at the 10−5 threshold, with six reaching this benchmark as early as day 28. Median progression-free survival has not been reached.

Liquid Handling System Market to Hit $7.79B by 2031, MarketsandMarkets Says

Image
Liquid Handling System Market to Hit $7.79B by 2031, MarketsandMarkets Says

Delray Beach, Fla. – September 26, 2026 -- The global liquid handling system market will grow from $5.26 billion in 2026 to $7.79 billion by 2031, expanding at a compound annual growth rate of 8.2%, according to a new report from MarketsandMarkets.

Automated systems and pipettes lead segment growth

Automated systems held the largest share of the market in 2025 and are projected to post the highest CAGR of 9.0% through 2031, as pharmaceutical and biotechnology laboratories shift from manual liquid transfer to robotic platforms for pipetting, dispensing, dilution and microplate handling. Within product categories, pipettes accounted for the largest 2025 share and are forecast to grow fastest at 9.5% CAGR, driven by adoption of electronic and multi-channel pipetting systems that integrate with laboratory information management systems (LIMS) and support nanoliter-scale dispensing for genomics and cell and gene therapy workflows.

Wriggle Box Launches Indiegogo Campaign for Sensory Play Structure

Image
Wriggle Box Launches Indiegogo Campaign for Sensory Play Structure

North Las Vegas, Nev. – – September 26, 2026 -- Wriggle Box LLC has launched an Indiegogo crowdfunding campaign for Wriggleworm, a full-body sensory regulation play structure aimed at autistic individuals, neurodivergent children and sensory seekers.

Wriggleworm delivers full-body pressure input paired with physical movement

The structure is engineered to mimic the sensation of digging through earth, delivering mild-to-moderate or deep, even pressure across the entire body as users move through it. Unlike single-point sensory tools such as squeeze devices or compression tubes, Wriggleworm combines tactile and proprioceptive feedback with active gross motor exertion.

IASO Bio Data Link CAR-T Persistence to Sustained MRD Negativity

Shanghai – September 26, 2026 -- A retrospective analysis of 102 multiple myeloma patients treated with IASO Bio's FUCASO CAR-T therapy found that patients maintaining sustained minimal residual disease (MRD) negativity showed a median CAR-T cell persistence of 463 days, compared with 272 days in patients who experienced MRD conversion — a gap of roughly 191 days. The data, drawn from the pivotal FUMANBA-1 registration study, were presented as a poster (Abstract No. PA-469) at the 2026 International Myeloma Society Annual Meeting.

Kali Therapeutics Named to Endpoints 11 After Sanofi Licensing Deal

Image
Kali Therapeutics Named to Endpoints 11 After Sanofi Licensing Deal

San Mateo, Calif. – September 25, 2026 -- Kali Therapeutics has been named one of the 11 most promising private biotechnology companies in the 2026 Endpoints 11, a list curated annually by Endpoints News editors from hundreds of private candidates.

Kali advanced two clinical candidates and closed a Sanofi licensing deal in just over two years

Founded in July 2024, the clinical-stage biotech moved from formation to two molecules in the clinic and a worldwide partnership with Sanofi inside roughly two years. The honorees were announced Thursday, September 24, 2026, at an awards gala at The State Room in Boston.